Doma (Drug Discovery) Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 12

Doma (Drug Discovery) General Information

Description

Developer of biotechnology products designed to provide an independent drug research and development pipeline. The company utilizes common light-chain antibody platforms and topoisomerase-inhibitor payload systems to develop bispecific antibody-drug conjugates, enabling the oncology market to access targeted therapeutics for advanced solid tumors.

Contact Information

Website
www.domabio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3rd Floor, Building C29, Biomedical Industrial Park
  • Number 218 Xinghu Street
  • Suzhou, Jiangsu 215128
  • China
+86 0512
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Impact Investing, Life Sciences, Oncology
Corporate Office
  • 3rd Floor, Building C29, Biomedical Industrial Park
  • Number 218 Xinghu Street
  • Suzhou, Jiangsu 215128
  • China
+86 0512

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Doma (Drug Discovery) Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC 17-Jan-2023 Completed Generating Revenue
1. Early Stage VC (Series A) 31-May-2022 Completed Generating Revenue
To view Doma (Drug Discovery)’s complete valuation and funding history, request access »

Doma (Drug Discovery) Patents

  • 8

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 4

    Pending

  • Expiring in next 12 mo

Doma (Drug Discovery) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023300794-A1 Anti-egfr/met antibodies and uses thereof Pending 29-Jun-2022
EP-4519321-A1 Anti-egfr/met antibodies and uses thereof Pending 29-Jun-2022
EP-4519321-A4 Anti-egfr/met antibodies and uses thereof Pending 29-Jun-2022
US-20250122292-A1 Anti-egfr/met antibodies and uses thereof Pending 29-Jun-2022
WO-2024002256-A1 Anti-egfr/met antibodies and uses thereof Inactive 29-Jun-2022 C07K16/2863
To view Doma (Drug Discovery)’s complete patent history, request access »

Doma (Drug Discovery) Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
State Development and Investment Group Government Minority
Biocytogen Pharmaceuticals (Beijing) Co Corporation Minority
China Life Private Equity PE/Buyout Minority
China Taiping Investment Venture Capital Minority
CMB International Capital Asset Manager Minority
You’re viewing 5 of 12 investors. Get the full list »

Ready to get started?

Request a free trial

Doma (Drug Discovery) FAQs

  • When was Doma (Drug Discovery) founded?

    Doma (Drug Discovery) was founded in 2021.

  • Where is Doma (Drug Discovery) headquartered?

    Doma (Drug Discovery) is headquartered in Suzhou, China.

  • What industry is Doma (Drug Discovery) in?

    Doma (Drug Discovery)’s primary industry is Drug Discovery.

  • Is Doma (Drug Discovery) a private or public company?

    Doma (Drug Discovery) is a Private company.

  • What is Doma (Drug Discovery)’s current revenue?

    The current revenue for Doma (Drug Discovery) is .

  • How much funding has Doma (Drug Discovery) raised over time?

    Doma (Drug Discovery) has raised $142M.

  • Who are Doma (Drug Discovery)’s investors?

    State Development and Investment Group, Biocytogen Pharmaceuticals (Beijing) Co, China Life Private Equity, China Taiping Investment, and CMB International Capital are 5 of 12 investors who have invested in Doma (Drug Discovery).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process